Thiazolidinedione use and retinal fluid in the comparison of age-related macular degeneration treatments trials

Conclusions In this exploratory analysis, patients with diabetes taking thiazolidinediones and treated with bevacizumab or ranibizumab for nAMD had worse baseline mean VA, greater reductions in subretinal and subretinal tissue complex thickness from baseline, and greater proportions with IRF comparing to patients not taking thiazolidinediones. Trial registration number ClinicalTrials.gov NCT00593450.

http://bjo.bmj.com/cgi/content/short/107/7/1000?rss=1

Source: British Journal of Ophthalmology - June 22, 2023 Category: Opthalmology Authors: Core, J. Q., Hua, P., Daniel, E., Grunwald, J. E., Jaffe, G., Maguire, M. G., Ying, G.-s., for the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Williams, Beardsley, Bennett, Cantrill, Chan-Tram, Cheshier, Davies, Tags: Original articles - Clinical science Source Type: research